The intensity of the anti-allograft response and the fragility of the transplanted organ may explain the lack of efficacy when Treg infusion is delayed. However, if T cell-depleting reagents such as ATG are used LBH589 order as induction therapy, it may be possible to delay Treg infusion until lymphocyte numbers start to recover 2 months or more after transplantation. This might tip the balance between Tregs and Teff cells and help to promote a tolerant state.

An additional consideration regarding Treg therapy is the site of action of Tregs and, consequently, the desired homing properties of injected cells. In the transplant setting, Treg lymph node homing and their ability to traffic to grafts are both required for their protection against graft rejection [83]. Interestingly, https://www.selleckchem.com/products/nutlin-3a.html in a mouse islet transplant model, therapeutic Tregs function initially at the graft site (preventing the exit of donor-derived DCs) and then traffic to the draining lymph node and continue to exert their suppressive function there [84]. In so doing, they prevent the exit and migration of

donor-derived DCs to the lymph nodes, thereby reducing alloimmune priming. The translation of such a study to the clinic may mean that to ensure that Tregs exert their suppressive function we need to either inject the cells at the graft site or ensure that the cells reach the graft/lymph node due either to their alloantigen specificity or homing receptor expression. Bearing in mind the serious complications associated with injection of the cells at the graft site, i.e. the risk of bleeding if cells are injected via the portal vein (in the HAS1 case of liver transplantation), the

favoured option is infusion via a peripheral vein. Studies have shown antigen-specific Tregs to be more potent than polyclonally activated Treg cells [85-87]. Moreover, Tregs with direct specificity are very potent in preventing acute rejection early after transplantation, while Tregs with indirect specificity seem to be crucial to prevent chronic rejection [42, 46]. In addition, using antigen-specific Tregs would have additional advantages; first, their action would be limited to the site of alloantigen source and immune activation [88, 89]; and secondly, this may avoid the undesirable pan-suppression, mediated by polyclonal cells, resulting in an increased risk of infections and cancers. However, although the expansion of direct pathway allospecific human Tregs has been achieved [90, 91], expansion of indirect pathway Tregs has proved more difficult, posing further challenges [92, 93].